enGene Therapeutics Inc. ENGN
1.75 USD +0.07 (+4.17%)
At closeNov 6, 2026, 4:00 PM EST
1.75 0.00 0.00%
After hours · Nov 6, 4:00 PM ET
1.63 Day range 1.78
1.44 52-week range 12.17
- YTD
- -80.62%
- 1 year
- -70.93%
- Market cap
- 117.28M
- EPS (ttm)
- -2.07
- Shares out
- 50.98M
- Forward P/E
- -3.53
- YTD return
- -80.62%
- 1-year return
- -70.93%
- Volume
- 1.43M
- Avg volume
- 788.64K
- Open
- 1.68
- Previous close
- 1.68
- Day's range
- 1.63 – 1.78
- 52-week range
- 1.44 – 12.17
- Beta
- -0.76
- Analysts
- Strong Buy
- Price target
- 27.00 (+1442.9%)
ALL -8.11 (-82.25%)
Key statistics
- Enterprise value
- 30.70M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.14
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -23.58M
- Total cash
- 257.68M
- Total debt
- 24.86M
- Return on equity
- -123.06%
- Short % of float
- 2.00%
- 50-day average
- 8.10
- 200-day average
- 10.01
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 27.00 +1442.9% upside
Now 1.75
- Target (low)
- 16.00
- Target (mean)
- 27.00
- Target (high)
- 37.00
Ratings (0m) 9 9 buy · 0 hold · 0 sell
- Strong buy4
- Buy5
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.3825.
Financials — quick view
ENGN Revenue — quarterly 0
ENGN Net income — quarterly -32.50M
ENGN EPS — quarterly -0.47
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Dec 23, 2024 | HC Wainwright & Co. | init | — | Buy |
| Dec 6, 2024 | JMP Securities | reit | Market Outperform | Market Outperform |
| Nov 27, 2024 | Raymond James | init | — | Outperform |
| Nov 18, 2024 | JMP Securities | init | — | Market Outperform |
| Sep 24, 2024 | Oppenheimer | reit | Outperform | Outperform |
About enGene Therapeutics Inc.
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a non-viral monotherapy to treat non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) in patients that have been unresponsive to treatment with Bacillus Calmette-Guérin (BCG). The company is based in Montreal, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- engene.com
News
enGene Holdings Inc. (NASDAQ:ENGN) Stock Has Average Price Target of $11.05 According to Brokerages 
Citizens Reiterates Market Perform on enGene Therapeuticsto Market Perform - enGene Holdings Q3 EPS $(0.47) Misses $(0.43) Estimate
EnGene Therapeutics Appoints Michael Heffernan Board Chairman, Effective Immediately, Succeeding Richard Glickman 
This Intuit Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday 
Morgan Stanley Downgrades enGene Therapeutics to Underweight 
W.P. Carey To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday 
HC Wainwright & Co. Maintains Buy on enGene Therapeutics, Lowers Price Target to $4 - EnGene Therapeutics Implements Workforce Reduction Of About 50% In June 2026; CFO Ryan Daws To Depart From Co, Effective July 15, 202
- enGene Holdings Q2 EPS $(0.43) Beats $(0.47) Estimate
Your note
Sign in to keep a note on ENGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRUNK GERALD A | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Feb 19, 2024 | 0 |
| CHEUNG ANTHONY TZEYEW | Chief Technology Officer | Conversion of Exercise of derivative security | Mar 17, 2024 | 102,873 |
| COOPER RONALD HAROLD WILFRED | Chief Executive Officer | Purchase | Sep 26, 2024 | 10,000 |
| FONDS DE SOLIDARITE DES TRAVAILLEURS DU | Beneficial Owner of more than 10% of a Class of Security | Sale | Apr 21, 2024 | 3,036,150 |
| FORBION GROWTH SPONSOR FEAC I B.V. | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Oct 26, 2023 | 0 |
| GLICKMAN RICHARD M | Director | Conversion of Exercise of derivative security | May 27, 2024 | 24,675 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fcpm III Services B.v. | 17.02% | 8,677,951 | 51.72M | Sep 29, 2024 |
| VR Adviser, LLC | 7.00% | 3,565,841 | 21.25M | Sep 29, 2024 |
| Blue Owl Capital Holdings LP | 6.00% | 3,058,969 | 18.23M | Sep 29, 2024 |
| Deep Track Capital, Lp | 5.12% | 2,607,633 | 15.54M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 4.57% | 2,329,768 | 13.89M | Sep 29, 2024 |
| BVF Inc. | 4.42% | 2,251,037 | 13.42M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Strategic Series-Franklin Biotechnology Discove | 0.53% | 272,359 | 1.62M | Jul 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 27,516 | 164.00K | Oct 30, 2024 |
| Northern Small Cap Core Fund | 0.02% | 11,000 | 65.56K | Sep 29, 2024 |